

Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

<https://marketpublishers.com/r/HF572BBE0AAEN.html>

Date: June 2017

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: HF572BBE0AAEN

Abstracts

Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 10 and 2 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies

Involved in Therapeutics Development

ActiveSite Pharmaceuticals Inc

Adverum Biotechnologies Inc

Arrowhead Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

Global Blood Therapeutics Inc

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences Inc

Shire Plc

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug

Profiles

ADVM-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AROF-12 - Drug Profile

Product Description

Mechanism Of Action
R&D Progress
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBT-18713 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKCLR_x - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKCR_x - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ilanadelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones

Featured News & Press Releases

May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial

May 22, 2017: Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 18, 2017: Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks

Mar 16, 2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE

Mar 06, 2017: Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI

Mar 01, 2017: Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE

Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial

Feb 23, 2017: New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease

Jan 16, 2017: European Commission amends Marketing Authorisation for RUCONEST to include self-administration

Dec 15, 2016: CHMP Adopts Extension To Existing Therapeutic Indication For Cinryze

Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL312 in Australia

Nov 14, 2016: Pharming Announces the Presentation of the Results of the RUCONEST Phase II study for Prophylaxis of Hereditary Angioedema Attacks

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd.1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant
Projects, H1 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -
Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

ActiveSite Pharmaceuticals Inc
Adverum Biotechnologies Inc
Arrowhead Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
Global Blood Therapeutics Inc
iBio Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Pharming Group NV
ProMetic Life Sciences Inc
Shire Plc

I would like to order

Product name: Hereditary Angioedema (HAE) - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/HF572BBE0AAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF572BBE0AAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970